Airiver Medical

Airiver Medical is a private, clinical-stage medical device company pioneering a drug-coated balloon platform for respiratory conditions. The company has secured two FDA Investigational Device Exemption (IDE) approvals in 2025 for pivotal studies in chronic rhinosinusitis and benign central airway stenosis, marking a significant step toward commercialization. With a seasoned leadership team from major medtech firms, Airiver is positioned to address large, underserved markets where current treatments often require repeated interventions. The company is currently pre-revenue as it advances its pivotal clinical programs.

Minimally invasive drug-coated balloon (DCB) platform designed to dilate narrowed passages and deliver anti-proliferative/anti-inflammatory drugs locally to prevent restenosis and recurrence in the airways and sinuses.

In central airway stenosis, competition includes standard-of-care mechanical balloon dilators, rigid bronchoscopy, and silicone/metallic stents from companies like Boston Scientific and Medtronic, but no FDA-approved drug-eluting device exists. In CRS, competitors include sinus dilation balloons (from Intersect ENT/Medtronic, Stryker) and various surgical tools, but again, no approved drug-coated device is marketed, positioning Airiver's technology as a potential first-in-class offering in both fields.